Suppr超能文献

JNJ-31020028(N-(4-{4-[2-(二乙氨基)-2-氧代-1-苯乙基]哌嗪-1-基}-3-氟苯基)-2-吡啶-3-基苯甲酰胺)的体外和体内特征,这是一种新型小分子神经肽 Y Y(2)受体选择性脑穿透拮抗剂。

In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor.

机构信息

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, USA.

出版信息

Psychopharmacology (Berl). 2010 Feb;208(2):265-77. doi: 10.1007/s00213-009-1726-x. Epub 2009 Dec 2.

Abstract

RATIONALE

The lack of potent, selective, brain penetrant Y(2) receptor antagonists has hampered in vivo functional studies of this receptor.

OBJECTIVE

Here, we report the in vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y(2) receptor antagonist.

METHODS

The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y(2) receptors in KAN-Ts cells and rat Y(2) receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y(2) bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.

RESULTS

JNJ-31020028 bound with high affinity (pIC(50) = 8.07 +/- 0.05, human, and pIC(50) = 8.22 +/- 0.06, rat) and was >100-fold selective versus human Y(1), Y(4), and Y(5) receptors. JNJ-31020028 was demonstrated to be an antagonist (pK(B) = 8.04 +/- 0.13) in functional assays. JNJ-31020028 occupied Y(2) receptor binding sites (approximately 90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.

CONCLUSION

These results suggest that Y(2) receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.

摘要

原理

缺乏有效、选择性强、能穿透血脑屏障的 Y2 受体拮抗剂,阻碍了该受体的体内功能研究。

目的

本研究报告了新型 Y2 受体拮抗剂 JNJ-31020028(N-(4-{4-[2-(二乙氨基)-2-氧代-1-苯乙基]哌嗪-1-基}-3-氟苯基)-2-吡啶-3-基苯甲酰胺)的体外和体内特征。

方法

通过抑制 KAN-Ts 细胞中人 Y2 受体与 PYY 的结合和大鼠海马中大鼠 Y2 受体与 PYY 的结合,测定 JNJ-31020028 的亲和力。通过抑制在表达嵌合 G 蛋白 Gqi5 的 KAN-Ts 细胞和大鼠输精管(典型的 Y2 生物测定)中 PYY 刺激的钙反应,测定其功能活性。通过受体放射自显影揭示体外受体占有率。通过微透析、焦虑模型和皮质酮释放,对 JNJ-31020028 进行体内测试。

结果

JNJ-31020028 与高亲和力结合(pIC50=8.07 +/- 0.05,人,和 pIC50=8.22 +/- 0.06,大鼠),对人 Y1、Y4 和 Y5 受体的选择性 >100 倍。在功能测定中,JNJ-31020028 被证明是一种拮抗剂(pK(B)=8.04 +/- 0.13)。JNJ-31020028 在大鼠皮下给药后可占据 Y2 受体结合位点(约 90%,10mg/kg)。JNJ-31020028 增加了下丘脑去甲肾上腺素的释放,这与去甲肾上腺素和神经肽 Y 的共定位一致。在多种焦虑模型中,JNJ-31020028 被发现无效,尽管它确实阻断了应激引起的皮质酮升高,但不改变基础水平,并在不影响基础摄食量的情况下,使应激动物的食物摄入量正常化。

结论

这些结果表明,Y2 受体可能不是啮齿动物急性行为的关键,但可能发挥调节作用,只有在特定情况下才能阐明这些作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验